6,455 Shares in Edwards Lifesciences Co. (NYSE:EW) Purchased by Crux Wealth Advisors

Crux Wealth Advisors bought a new position in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 6,455 shares of the medical research company's stock, valued at approximately $478,000.

Several other large investors have also recently modified their holdings of the business. Vanguard Group Inc. boosted its holdings in Edwards Lifesciences by 10.4% in the 4th quarter. Vanguard Group Inc. now owns 69,132,036 shares of the medical research company's stock worth $5,117,845,000 after buying an additional 6,537,494 shares during the period. Wellington Management Group LLP boosted its holdings in shares of Edwards Lifesciences by 5.3% in the fourth quarter. Wellington Management Group LLP now owns 33,210,879 shares of the medical research company's stock worth $2,458,601,000 after acquiring an additional 1,678,154 shares during the period. Geode Capital Management LLC grew its position in shares of Edwards Lifesciences by 0.9% in the fourth quarter. Geode Capital Management LLC now owns 13,647,341 shares of the medical research company's stock valued at $1,007,520,000 after purchasing an additional 126,194 shares in the last quarter. Fisher Asset Management LLC raised its stake in shares of Edwards Lifesciences by 7.7% during the 4th quarter. Fisher Asset Management LLC now owns 9,775,276 shares of the medical research company's stock valued at $723,664,000 after purchasing an additional 696,965 shares during the period. Finally, Norges Bank purchased a new stake in Edwards Lifesciences during the 4th quarter worth about $610,895,000. Hedge funds and other institutional investors own 79.46% of the company's stock.

Insider Buying and Selling at Edwards Lifesciences

In other news, Director Steven R. Loranger sold 5,739 shares of the firm's stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $76.42, for a total value of $438,574.38. Following the completion of the sale, the director now directly owns 60,372 shares of the company's stock, valued at approximately $4,613,628.24. This trade represents a 8.68 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP Donald E. Bobo, Jr. sold 6,500 shares of the business's stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $75.75, for a total transaction of $492,375.00. Following the transaction, the vice president now owns 46,936 shares in the company, valued at $3,555,402. This represents a 12.16 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 71,853 shares of company stock worth $5,163,062. 1.29% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. Canaccord Genuity Group upped their price target on Edwards Lifesciences from $68.00 to $71.00 and gave the company a "hold" rating in a research report on Thursday, February 13th. Piper Sandler increased their target price on shares of Edwards Lifesciences from $70.00 to $73.00 and gave the stock a "neutral" rating in a research note on Wednesday, February 12th. Wolfe Research lowered shares of Edwards Lifesciences from a "hold" rating to a "strong sell" rating in a research report on Wednesday, February 12th. Morgan Stanley increased their price objective on Edwards Lifesciences from $70.00 to $75.00 and gave the stock an "equal weight" rating in a research report on Wednesday, February 12th. Finally, Barclays boosted their target price on Edwards Lifesciences from $88.00 to $90.00 and gave the stock an "overweight" rating in a research report on Thursday, February 13th. One research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $78.55.

Edwards Lifesciences Trading Up 0.7 %

Shares of NYSE:EW traded up $0.50 on Thursday, reaching $71.70. 1,555,061 shares of the company traded hands, compared to its average volume of 4,905,765. The stock has a market capitalization of $42.15 billion, a P/E ratio of 10.30, a price-to-earnings-growth ratio of 4.82 and a beta of 1.15. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $95.25. The business's 50-day simple moving average is $71.29 and its 200 day simple moving average is $70.76. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, topping analysts' consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. As a group, equities analysts anticipate that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.